PMID: 15226619Jul 1, 2004Paper

Gemtuzumab ozogamicin and targeted cancer therapy

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Masahiro Imaizumi

Abstract

Recently, anti-cancer antibodies have been launched in Japan and also immunoconjugates with a cytotoxic compound or a radioisotope have been launched in the USA. Gemtuzumab ozogamicin is a conjugate of anti-CD33 antibody and a cytotoxic calicheamicin derivative. After binding the CD33-positive leukemia cells, gemtuzumab ozogamicin is internalized and releases the calicheamicin derivative. The calichemicin derivative breaks DNA and kills the cells. Gemtuzumab ozogamicin was effective and well tolerated in clinical trials in patients with acute myeloid leukemia (AML) in relapse. It was approved in 2000 by the FDA, and Wyeth K.K. has submitted it as an anti-tumor drug for CD33 positive AML. Two kinds of immunoconjugates, anti-CD20 antibodies with radioisotopes, recently have been launched in the USA for CD20-positive non-Hodgkin's lymphoma. These conjugates showed efficacy in patients who are refractory to the conventional chemotherapies. Targeted therapy with the immunoconjugate that can deliver cytotoxic compounds to specific cells is promising for use in oncology.

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S WalkerD Kahne
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T E WitzigA J Grillo-López
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseM S Kaminski
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversUNKNOWN Mylotarg Study Group
Oct 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S KaminskiJ M Vose
Mar 16, 2002·Blood·Pankaj RajvanshiGeorge B McDonald
Apr 30, 2003·Seminars in Oncology·Alessandra Cesano, Urte Gayko
Aug 7, 2003·Current Opinion in Pharmacology·Nitin K Damle, Philip Frost
Nov 26, 2003·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Shin-ichi Nihira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.